Ovarian Cancer

Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme. Read More

Blood type A was associated with longer ovarian cancer survival in a recent Vanderbilt-led study. Read More

Fall fashions for women will be on display during the 4th Annual Chic Awearness Fashion Show promoting ovarian cancer awareness and research. The event, to be held Monday, Sept. 26, 6:30 to 8:30 p.m., will benefit the T.J. Martell Foundation, which supports ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC). Read More

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer. Read More

Drugs that target DNA damage improve ovarian cancer cell response to platinum chemotherapies, suggesting new therapeutic opportunities. Read More

Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer. Read More

The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments. Read More

Combining another drug with platinum-based chemotherapies may be more effective against ovarian cancer. Read More